Windlas Biotech Ltd

Drug Manufacturers-Specialty & Generic

Prices are adjusted according to historical splits.

Windlas Biotech Ltd Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
₹4.94 billion
Book Value:
Revenue TTM:
₹4.95 billion
Operating Margin TTM:
Gross Profit TTM:
₹1.58 billion
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Windlas Biotech Ltd had its IPO on under the ticker symbol WINDLAS.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Windlas Biotech Ltd has a staff strength of 962 employees.

Stock update

Shares of Windlas Biotech Ltd opened at ₹373.05 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹347.85 - ₹374.45, and closed at ₹357.9.

This is a -3.45% slip from the previous day's closing price.

A total volume of 5,898 shares were traded at the close of the day’s session.

In the last one week, shares of Windlas Biotech Ltd have slipped by -7.09%.

Windlas Biotech Ltd's Key Ratios

Windlas Biotech Ltd has a market cap of ₹4.94 billion, indicating a price to book ratio of 1.3622 and a price to sales ratio of 1.1069.

In the last 12-months Windlas Biotech Ltd’s revenue was ₹4.95 billion with a gross profit of ₹1.58 billion and an EBITDA of ₹567.96 million. The EBITDA ratio measures Windlas Biotech Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Windlas Biotech Ltd’s operating margin was 9.29% while its return on assets stood at 5.74% with a return of equity of 11.57%.

In Q4, Windlas Biotech Ltd’s quarterly earnings growth was a positive 11% while revenue growth was a positive 1.8%.

Windlas Biotech Ltd’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at ₹21.29 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Windlas Biotech Ltd’s profitability.

Windlas Biotech Ltd stock is trading at a EV to sales ratio of 0.765 and a EV to EBITDA ratio of 5.5939. Its price to sales ratio in the trailing 12-months stood at 1.1069.

Windlas Biotech Ltd stock pays annual dividends of ₹0 per share, indicating a yield of 1.5% and a payout ratio of 16.43%.

Balance sheet and cash flow metrics

Total Assets
₹5.18 billion
Total Liabilities
₹1.07 billion
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Windlas Biotech Ltd ended 2024 with ₹5.18 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹5.18 billion while shareholder equity stood at ₹4.08 billion.

Windlas Biotech Ltd ended 2024 with ₹0 in deferred long-term liabilities, ₹1.07 billion in other current liabilities, 108970000.00 in common stock, ₹0 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹219.08 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹2.62 million.

Windlas Biotech Ltd’s total current assets stands at ₹4.04 billion while long-term investments were ₹0 and short-term investments were ₹1.63 billion. Its net receivables were ₹1.05 billion compared to accounts payable of ₹786.45 million and inventory worth ₹821.77 million.

In 2024, Windlas Biotech Ltd's operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, Windlas Biotech Ltd paid ₹0.16 in dividends in 2024.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Windlas Biotech Ltd stock is currently trading at ₹357.9 per share. It touched a 52-week high of ₹279.836 and a 52-week low of ₹279.836. Analysts tracking the stock have a 12-month average target price of .

Its 50-day moving average was ₹347.44 and 200-day moving average was ₹278.13 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 6207% of the company’s stock are held by insiders while 1126.3% are held by institutions.

Frequently Asked Questions About Windlas Biotech Ltd

The stock symbol (also called stock or share ticker) of Windlas Biotech Ltd is WINDLAS

The IPO of Windlas Biotech Ltd took place on

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Kopran Limited (KOPRAN)

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


Windlas Biotech Limited, contract development and manufacturing organization (CDMO), manufactures and trades in pharmaceutical products in India. It offers CDMO services, including product discovery, product development, licensing, and commercial manufacturing of generic products. The company also provides manufactures various domestic trade generics and over-the-counter brands, which include nutraceutical and health supplement products through the online and offline channels. In addition, it manufactures pills, capsules, pouches, sachets, and liquid bottles; and generic products portfolio comprises fixed dosage combinations, fixed dosage plus modified release combinations, customized generics, and chewable or dispersible. It exports its products primarily to Cambodia, Ivory Coast, the Philippines, Thailand, Vietnam, Myanmar, and Sri Lanka. The company was incorporated in 2001 and is based in Gurugram, India.


705-706, Vatika Professional Point, Gurugram, India, 122001